


# Q1 2023 Results

Speakers
Dr. Yoav Zeif, CEO
Eitan Zamir, CFO
Yonah Lloyd, CCO & VP IR

May 16, 2023



# **Conference Call and Webcast Details**


US Toll-Free Dial-In 1-877-407-0619

International Dial-In 1-412-902-1012

**Live Webcast and Replay** 

https://event.choruscall.com/mediaframe/webcast.


html?webcastid=f4rFQOPp



# Forward-Looking Statements

## **Cautionary Statement Regarding Forward-Looking Statements**

The statements in this slide presentation regarding Stratasys' strategy, and the statements regarding its projected future financial performance, including the financial guidance concerning its expected results for 2023, are forward-looking statements reflecting management's current expectations and beliefs. These forward-looking statements are based on current information that is, by its nature, subject to rapid and even abrupt change. Due to risks and uncertainties associated with Stratasys' business, actual results could differ materially from those projected or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: the degree of our success at introducing new or improved products and solutions that gain market share; the extent of growth of the 3D printing market generally; the duration and severity of headwinds caused by current macro-economic trends that have been adversely affecting, and may continue to adversely affect, our results, including unfavorable currency exchange rates, supply-chain delays, inflationary pressures and rising interest rates; the impact of potential shifts in the prices or margins of the products that we sell or services that we provide, including due to a shift towards lower margin products or services; the impact of competition and new technologies; the extent of our success at successfully integrating into our existing business, or making additional, acquisitions or investments in new businesses, technologies, products or services; potential changes in our management and board of directors; global market, political and economic conditions, and in the countries in which we operate in particular (including risks stemming from Russia's invasion of Ukraine); potential further charges against earnings that we could be required to take due to impairment of additional goodwill or other intangible assets that we have recently acquired or may acquire in the future; costs and potential liability relating to litigation and regulatory proceedings; risks related to infringement of our intellectual property rights by others or infringement of others' intellectual property rights by us; the extent of our success at maintaining our liquidity and financing our operations and capital needs; the impact of tax regulations on our results of operations and financial condition; and those additional factors referred to in Item 3.D "Key Information - Risk Factors", Item 4, "Information on the Company", Item 5, "Operating and Financial Review and Prospects," and all other parts of our Annual Report on Form 20-F for the year ended December 31, 2022, to be filed with the SEC on or about March 2, 2023 (the "2022 Annual Report"). Readers are urged to carefully review and consider the various disclosures made throughout our 2022 Annual Report and the Reports of Foreign Private Issuer on Form 6-K that attach Stratasys' unaudited, condensed consolidated financial statements and its review of its results of operations and financial condition, for the quarterly periods throughout 2023, which Stratasys will be furnishing to the SEC over the course of 2023, and our other reports filed with or furnished to the SEC, which are designed to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects. Any guidance provided, and other forward-looking statements made, in this slide presentation are made as of the date hereof, and Stratasys undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.



# **Use of Non-GAAP Financial Information**

#### **Use of Non-GAAP Financial Measures**


The non-GAAP data included herein, which excludes certain items as described below, are non-GAAP financial measures. Our management believes that these non-GAAP financial measures are useful information for investors and shareholders of our Company in gauging our results of operations (i) on an ongoing basis after excluding mergers, acquisitions and divestments related expense or gains and reorganization-related charges or gains, legal provisions, and (ii) excluding non-cash items such as stockbased compensation expenses, acquired intangible assets amortization, including intangible assets amortization related to equity method investments, impairment of long-lived assets and goodwill, revaluation of our investments and the corresponding tax effect of those items. The items eliminated via these non-GAAP adjustments either do not reflect actual cash outlays that impact our liquidity and our financial condition or have a non-recurring impact on the statement of operations, as assessed by management. These non-GAAP financial measures are presented to permit investors to more fully understand how management assesses our performance for internal planning and forecasting purposes. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of our results of operations without including all items indicated above during a period, which may not provide a comparable view of our performance to other companies in our industry. Investors and other readers should consider non-GAAP measures only as supplements to, not as substitutes for or as superior measures to, the measures of financial performance prepared in accordance with GAAP. Reconciliation between results on a GAAP and non-GAAP basis is provided in a table later in this slide presentation.



## **Nano Dimension Update**

- Stratasys' Board received three unsolicited proposals to acquire Stratasys for \$18.00, \$19.55, and \$20.05 per share in cash.
- After careful review, the Board unanimously rejected each proposal because they substantially undervalue Stratasys in light of the Company's standalone prospects.
- Nano is in midst of multiple lawsuits with its shareholders involving the control and governance of their company and, as a result, serious questions remain about the legitimacy of the Nano offer.
- We are committed to enhancing shareholder value and executing on Stratasys' growth strategy. We are making strong progress towards becoming a highly profitable, \$1 billion revenue company. As part of its fiduciary duties, the Board will review any bona fide proposal for the company and weigh it against our standalone plan.





**Dr. Yoav Zeif** CEO

- Excellent Q1 results against a challenging environment and on track for \$1 billion revenue by 2026 with substantial profitability
- Strong printer utilization drove record consumables and customer service revenue
- Growing trends of onshoring, de-globalization driving opportunities our way
- Positive adj. EPS for 7<sup>th</sup> consecutive quarter
- Strong balance sheet with \$288M cash and equivalents, no debt

### Q1 Highlights: New Dental Solutions for \$50B Dental Parts Industry

# First Monolithic, Multi-Color 3D Printed Dentures Solution

- TrueDent FDA-cleared resin works exclusively with J5 DentaJet printer
- Dentures represent \$5B+ opportunity in US - only 5% are created digitally today
- Several early wins already secured



# **New Entry-Level Printer for Smaller Dental Labs**


- J3 DentaJet 3D printer targets SMB labs representing two-thirds of market
- Move labs from low-accuracy, single-material desktop printers to our superior solution
- Large dental lab tripled productivity



### Q1 Highlights: Growing New Markets in Personalized Healthcare


# Patient-Specific Solution Delivered as Cloud Service

- Agreement with Ricoh USA provides ondemand 3D-printed anatomic models
- Complete cloud solution combines our 3DP technology with Axial3D slicing software and Ricoh manufacturing services



#### **Industrial-Scale BioPrinting**

- Stratasys and CollPlant unite technologies to develop solution for \$2.6 billion addressable market
- Initial focus on breast implant market with ability to expand to other tissues and organs



### Q1 Highlights: Executing Our Manufacturin Growth Strategy

# German Manufacturer Adds 4 More H350 3D Printers

- Götz Maschinenbau fleet now includes 6 systems
- Builds on existing fleets of FDM and PolyJet printers



#### **Covestro AM Acquisition Closed**

- Expands materials portfolio for stereolithography, DLP, and powders - 60 new materials
- Immediately accretive
- R&D facilities, development and sales teams



### Q1 Highlights: Adding Value and Recurring Software Revenue

# Introducing GrabCAD Print Pro

- Annual license fee, initially for FDM and SAF customers
- Includes quality management technology from Riven
- New 3<sup>rd</sup>-party partners Castor, AlphaSTAR, Cognitive Design Systems add functionality




#### **Industry 4.0 Project**

- Successfully integrated GrabCAD platform into Factory+ Industry
   4.0 architecture at the UK's Advanced Manufacturing
   Research Centre
- Demonstrates ability to integrate
   Stratasys technology alongside
   traditional factory floor equipment



# OpenAM Software Now Generally Available

 Materials flexibility and access to advanced settings helping contribute to new Fortus 450mc printer sales opportunities




## **CFO Remarks**



**Eitan Zamir** CFO

- Solid results in an increasingly challenging environment
- Tight OPEX management and right infrastructure helped maintained gross and operating margins
- Efficiency efforts are paying off across the platform



## **Financial Results**

	GAAP			Non-GAAP			
	Q1-22	Q1-23	Change Y/Y	Q1-22	Q1-23	Change Y/Y	
Total Revenue	163.4	149.4	-8.6%	163.4	149.4	-8.6%	
Gross Profit	69.7	65.4	(4.3)	77.4	70.7	(6.7)	
• % Margin	42.6%	43.8%	1.2%	47.3%	47.3%	0.0%	
Operating Income (Loss)	(19.6)	(16.8)	2.8	2.0	1.5	(0.5)	
• % Margin	-12.0%	-11.2%	0.8%	1.2%	1.0%	-0.2%	
Net Income (Loss)	(20.9)	(22.2)	(1.3)	1.2	1.1	(0.1)	
• % Margin	-12.8%	-14.9%	-2.1%	0.7%	0.7%	0.0%	
Diluted EPS	(0.32)	(0.33)	(0.01)	0.02	0.02	(0.00)	
Diluted Shares	65.7	67.6	2.8%	67.1	68.1	1.5%	

Note: \$ in millions unless noted otherwise. All numbers and percentages rounded.

### Strong Printer Utilization Drove Record Consumables Revenue

Revenue of \$149.4 million down 8.6% YoY. OEM business down 0.9% at constant currency.

Product revenue down 10.7% vs. Q1 2022, down 5.1%, adjusted for divestitures and at constant currency.


Revenues - Q1'23

Consumables

Customer Support

Service

Services revenue down 3.9% vs. Q1 2022, up 3.9% adjusted for Stratasys Direct and at constant currency.



Revenue	Y/Y	Y/Y (exc. FX a		
Product	-10.7%	-5.1%		
<ul><li>System</li></ul>	-25.8%	-19.2%		

3.3%

-3.9%

4.9%

7.5%


-0.8%

6.4%

<sup>\*</sup> Reflects only 2 months of MakerBot revenue. Note: \$ in millions unless noted otherwise. All numbers and percentages rounded.

## **Gross Margins Demonstrate Focus on Cost Savings**


GAAP and Non-GAAP margins negatively impacted by FX, positively impacted by MakerBot carve-out



# **Operating Expenses Reflects Effective Scalability**


## **GAAP** expenses operating

(absolute and as a percentage of revenues)




## Non-GAAP operating expenses

(absolute and as a percentage of revenues)



\$7.1 million yr./yr. GAAP operating expenses reduction and \$6.1 million non-GAAP operating expenses reduction reflects continued effective cost management despite lower revenues.

## Seventh Straight Q of Positive Adj. EPS



Decreased non-GAAP Q1 operating income reflects decline in overall revenues, partially offset by 8.2% non-GAAP operating expenses.

Non-GAAP net income reflects a seventh consecutive quarter of delivering positive net income on an adjusted basis.


Note: \$ in millions unless noted otherwise. All numbers and percentages rounded.

# Fortified Balance Sheet and Responsible Use of Cash

#### **Balance sheet items**

	Q1-22	Q4-22	Q1-23
Cash and Cash Equivalents and Short-term deposits	475.6	327.8	287.6
Accounts Receivable	136.4	144.7	144.5
Inventories	143.1	194.1	202.0
Net Working Capital	586.8	489.6	462.9

## Cash flow from operating activities



Cash use was primarily driven by increased inventory purchases. We expect our inventory levels to decline in the back half of this year, contributing towards returning to positive cash flow from operations for 2023.

Strong balance sheet and cash generation leaves
Stratasys well-capitalized and positioned to capture value-enhancing market opportunities.

Note: \$ in millions unless noted otherwise. All numbers and percentages rounded.

## 2023 – Raising Revenue Outlook

#### Revenue

Sequential growth through the year

- 2023 range: \$630M-\$670M
  - Raised from \$620M-\$670M
- 2H notably stronger than 1H

#### **Operating Expenses**

Improving as a percent of revenue

2023 range: \$290M-\$300M

#### Earnings

Improvement momentum continues

- GAAP net loss of (\$1.12)-(\$0.83) per diluted share
- Non-GAAP net income \$0.12-\$0.24 per diluted share
- Adjusted EBITDA of \$35M-\$50M

#### **Gross Margins**

Improving, with stronger 2H

- 2023 range: 48.0%-49.0%
- Targeting above 50% in 2024

#### **Operating Margins**

Improving through the year

- Non-GAAP operating margins 2.5%-3.5%
- Expecting growth to double digits in medium term

#### **Capital Expenses**

2023 range: \$20M-\$25M

Positive Operating Cash Flow



### **Medium Term Outlook**


#### 2024

- Non-GAAP gross margins above 50%
- Positive free cash flow

#### 2026

- Revenues exceeding \$1 billion
- Adjusted EBITDA over 15% of revenues







**Dr. Yoav Zeif** CEO

- Outlook for 3D printing growth is strong
- Stratasys is best positioned to lead polymer 3DP with the broadest hardware, software and materials portfolio
- Seeing more strategic opportunities at the executive leadership levels of our customers
- Proven our value with industry leaders like TE Connectivity, Mayo Clinic, NASA and Toyota
- Investments and focused execution positioned to drive relative outperformance and enhance shareholder value



**strata**sys

# Thank You



## **Appendix**

	Three months ended March 31, 2023			Three months ended March 31, 2022		
	GAAP	Adjustments	Non-GAAP	GAAP	Adjustments	Non-GAAF
Gross Profit (1)	\$65,395	\$5,299	\$70,694	\$69,677	\$7,689	\$77,366
Operating income (Loss) (1,2)	(16,797)	18,315	1,518	(19,584)	21,607	2,023
Net income (Loss) (1,2,3)	(22,224)	23,306	1,082	(20,948)	22,158	1,210
Net income (Loss) per diluted share (4)	\$(0.33)	\$0.35	\$0.02	\$(0.32)	\$0.34	\$0.02
Acquired intangible assets amortization expense		4,001			6,966	
Non-cash stock-based compensation expense		932			900	
Restructuring and other related costs		366			(177)	
		5,299			7,689	
2) Acquired intangible assets amortization expense		2,194			2,225	
Non-cash stock-based compensation expense		7,308			7,633	
Restructuring and other related costs		1,798			555	
Revaluation of investment		580			1,061	
Contingent consideration		265			207	
Other expenses		871			2,237	
	13,016		13,918			
		18,315			<b>21</b> ,60 <b>7</b>	
3) Corresponding tax effect		3,038			145	
Equity method related amortization		1,490			-	
Finance expenses		463			406	
		\$23,306			\$22,158	
4) Weighted average number or ordinary shares outstanding – Diluted	67,583		68,080	65,721		67,060

Note: \$ in thousands unless noted otherwise. All numbers and percentages rounded.